Topics

Articles

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

US Government Considers Banning Dealings with WuXi AppTec, Affiliates

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection. 

AstraZeneca Intends to Make $831 Million Financial Commitment in the UK

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

Report: The Future of the Health Insurance Market Appears Stable

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective. 

Finding the Ideal Set of Oncology Employer Benefits 

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

Identifying Trends Surrounding the Use of In-House Pharmacies for High-Cost Drugs

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

Investigating Trends in the Pharmaceutical Research & Development Space

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications. 

Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina. 

DHL Supply Chain Invests $200M Toward Expanding Its Life Sciences and Healthcare Services

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Survey: Pharma Execs Are Fully Embracing the Use of AI 

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

Business and Finance